GRCE Grace Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1444192 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-173.9%
TTM EPS YoY-118.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-36.2%
ROA-34.5%
ROIC (approx.)-46.7%
Asset turnover—
Leverage & solvency
Liabilities / assets3.8%
Debt / equity0.00x
Current ratio13.61x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.42x
Accruals ratio-20.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q22026-09-30 | 2027Q12026-06-30 | 2026Q4*2026-03-31 | 2026Q32025-12-31 | 2026Q22025-09-30 | 2026Q12025-06-30 | 2025Q4*2025-03-31 | 2025Q32024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $885,000 | $697,000 | $420,000 | $462,000 | $568,000 | $955,000 | $1.63M | $2.19M |
| SG&A expense | $1.41M | $1.69M | $2.59M | $1.99M | $1.96M | $2.13M | $1.55M | $1.51M |
| Operating income | -$2.29M | -$15.92M | -$3.01M | -$2.45M | -$2.53M | -$3.09M | -$3.18M | -$3.70M |
| Pretax income | -$2.14M | -$15.79M | -$2.88M | -$2.31M | -$938,000 | -$3.36M | -$382,000 | -$4.76M |
| Income tax | -$8,000 | $0 | -$1.70M | $0 | $0 | $0 | -$1.02M | -$605,000 |
| Net income | -$2.13M | -$15.79M | -$1.18M | -$2.31M | -$938,000 | -$3.36M | $636,000 | -$4.16M |
| EBITDA | -$2.29M | -$15.91M | -$3.01M | -$2.45M | -$2.53M | -$3.09M | -$3.18M | -$3.70M |
| EPS (basic) | -0.11 | -0.91 | — | -0.14 | -0.06 | -0.21 | — | -0.36 |
| EPS (diluted) | -0.11 | -0.91 | — | -0.14 | -0.06 | -0.21 | — | -0.36 |
| Weighted avg. shares (diluted) | 20.12M | 17.27M | — | 16.93M | 15.92M | 15.92M | — | 11.51M |
| Balance sheet | ||||||||
| Cash & equivalents | $21.31M | $13.76M | $16.98M | $18.67M | $16.86M | $20.00M | $22.13M | $11.05M |
| Current assets | $21.96M | $14.33M | $17.38M | $19.21M | $17.30M | $20.52M | $22.71M | $11.94M |
| PP&E, net | — | — | $8,000 | — | — | — | $15,000 | — |
| Goodwill | $8.14M | $8.14M | $8.14M | $8.14M | $8.14M | $8.14M | $8.14M | $8.14M |
| Intangibles | $27.59M | $27.59M | $41.13M | $41.13M | $41.13M | $41.13M | $41.13M | $41.13M |
| Total assets | $57.70M | $50.07M | $66.65M | $68.49M | $66.58M | $69.81M | $71.99M | $61.22M |
| Current liabilities | $1.61M | $1.25M | $2.15M | $1.28M | $1.25M | $2.31M | $1.93M | $1.97M |
| Total liabilities | $2.22M | $1.86M | $2.76M | $3.60M | $3.76M | $6.25M | $5.38M | $9.09M |
| Shareholders' equity | $55.48M | $48.21M | $63.90M | $64.89M | $62.82M | $63.55M | $66.61M | $52.14M |
| Shares outstanding | 21.04M | 16.27M | 16.02M | 15.47M | 14.13M | 13.83M | 13.72M | 10.14M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.78M | -$3.22M | -$1.70M | -$2.23M | -$3.14M | -$1.80M | -$2.95M | -$4.12M |
| Investing cash flow | — | — | $0 | $0 | $0 | $0 | $0 | $15,000 |
| Financing cash flow | $9.34M | $0 | $0 | $4.04M | $0 | -$327,000 | $14.03M | $0 |
| Depreciation & amortization | $1,000 | $2,000 | $2,000 | $3,000 | $0 | $2,000 | $2,000 | $2,000 |
| Stock-based compensation | $197,000 | $105,000 | $182,000 | $108,000 | $206,000 | $302,000 | $130,000 | $160,000 |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.